Keeley-Teton Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $313K | Sell |
12,361
-992
| -7% | -$26K | 0.04% | 334 |
|
|
2024
Q4 | $354K | Sell |
13,353
-5,900
| -31% | -$160K | 0.04% | 330 |
|
|
2024
Q3 | $557K | Hold |
19,253
| – | – | 0.06% | 292 |
|
|
2024
Q2 | $539K | Hold |
19,253
| – | – | 0.07% | 274 |
|
|
2024
Q1 | $534K | Sell |
19,253
-1,780
| -8% | -$49.4K | 0.07% | 275 |
|
|
2023
Q4 | $606K | Sell |
21,033
-3,685
| -15% | -$111K | 0.08% | 255 |
|
|
2023
Q3 | $820K | Buy |
24,718
+1,500
| +6% | +$53K | 0.12% | 224 |
|
|
2023
Q2 | $852K | Sell |
23,218
-18,137
| -44% | -$706K | 0.11% | 235 |
|
|
2023
Q1 | $1.69M | Buy |
41,355
+1,546
| +4% | +$66.8K | 0.21% | 148 |
|
|
2022
Q4 | $2.04M | Buy |
39,809
+428
| +1% | +$20.5K | 0.25% | 118 |
|
|
2022
Q3 | $1.72M | Hold |
39,381
| – | – | 0.24% | 125 |
|
|
2022
Q2 | $2.06M | Sell |
39,381
-7,348
| -16% | -$374K | 0.26% | 113 |
|
|
2022
Q1 | $2.42M | Buy |
46,729
+2,393
| +5% | +$124K | 0.25% | 131 |
|
|
2021
Q4 | $2.62M | Buy |
44,336
+6,000
| +16% | +$297K | 0.28% | 118 |
|
|
2021
Q3 | $1.65M | Sell |
38,336
-839
| -2% | -$37.2K | 0.18% | 176 |
|
|
2021
Q2 | $1.53M | Sell |
39,175
-1,496
| -4% | -$58.2K | 0.16% | 192 |
|
|
2021
Q1 | $1.47M | Buy |
40,671
+927
| +2% | +$32.9K | 0.15% | 191 |
|
|
2020
Q4 | $1.46M | Sell |
39,744
-1,505
| -4% | -$55.2K | 0.2% | 152 |
|
|
2020
Q3 | $1.44M | Hold |
41,249
| – | – | 0.23% | 139 |
|
|
2020
Q2 | $1.28M | Sell |
41,249
-1,006
| -2% | -$34.2K | 0.2% | 150 |
|
|
2020
Q1 | $1.31M | Sell |
42,255
-1,204
| -3% | -$41K | 0.23% | 134 |
|
|
2019
Q4 | $1.61M | Sell |
43,459
-1,614
| -4% | -$57.5K | 0.17% | 158 |
|
|
2019
Q3 | $1.54M | Buy |
45,073
+722
| +2% | +$26.3K | 0.16% | 159 |
|
|
2019
Q2 | $1.82M | Hold |
44,351
| – | – | 0.18% | 161 |
|
|
2019
Q1 | $1.79M | Hold |
44,351
| – | – | 0.16% | 152 |
|
|
2018
Q4 | $1.84M | Hold |
44,351
| – | – | 0.18% | 136 |
|
|
2018
Q3 | $1.85M | Sell |
44,351
-211
| -0.5% | -$8.12K | 0.13% | 159 |
|
|
2018
Q2 | $1.53M | Sell |
44,562
-105
| -0.2% | -$3.59K | 0.11% | 184 |
|
|
2018
Q1 | $1.5M | Sell |
44,667
-1,265
| -3% | -$43.5K | 0.1% | 186 |
|
|
2017
Q4 | $1.58M | Sell |
45,932
-422
| -0.9% | -$14.4K | 0.1% | 179 |
|
|
2017
Q3 | $1.57M | Sell |
46,354
-390
| -0.8% | -$12.5K | 0.08% | 175 |
|
|
2017
Q2 | $1.49M | Hold |
46,744
| – | – | 0.07% | 175 |
|
|
2017
Q1 | $1.52M | Buy |
+46,744
| New | +$1.47M | 0.07% | 184 |
|
Other funds holding PFE
TIM
Keeley-Teton Advisors's PFE Position: Q1 2025 in Review
Keeley-Teton Advisors reduced its Pfizer (PFE) stake by 7.4% in Q1 2025, selling an estimated $26K and leaving 12,361 shares worth $313K. The position accounts for 0.04% of the portfolio, ranked #334.
Keeley-Teton Advisors first reported a position in PFE in Q1 2017 and has held it in 33 quarters since. The position peaked at $2.62M in Q4 2021. 2,930 funds tracked by Wall St. Rank hold PFE as of Q1 2025.
- Keeley-Teton Advisors held 12,361 shares of Pfizer worth $313K as of Q1 2025.
- Keeley-Teton Advisors sold 992 Pfizer shares in Q1 2025, an estimated $26K.
- Pfizer made up 0.04% of Keeley-Teton Advisors's portfolio in Q1 2025, its #334 holding.
- Keeley-Teton Advisors first reported a position in Pfizer in Q1 2017 and has held it in 33 quarters since.
- Keeley-Teton Advisors's Pfizer position peaked at $2.62M in Q4 2021.
- 2,930 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.
Based on Keeley-Teton Advisors's 13F filing for Q1 2025, filed 14 May 2025.